Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

PURPOSE: The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Boonsri, Boonyakorn, Yacqub-Usman, Kiren, Thintharua, Pakpoom, Myint, Kyaw Zwar, Sae-Lao, Thannicha, Collier, Pam, Suriyonplengsaeng, Chinnawut, Larbcharoensub, Noppadol, Balasubramanian, Brinda, Venkatraman, Simran, Egbuniwe, Isioma U., Gomez, Dhanwant, Mukherjee, Abhik, Kumkate, Supeecha, Janvilisri, Tavan, Zaitoun, Abed M, Kuakpaetoon, Thiti, Tohtong, Rutaiwan, Grabowska, Anna M, Bates, David O., Wongprasert, Kanokpan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053863/
https://www.ncbi.nlm.nih.gov/pubmed/33070556
http://dx.doi.org/10.4143/crt.2020.585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053863/
https://www.ncbi.nlm.nih.gov/pubmed/33070556
http://dx.doi.org/10.4143/crt.2020.585

Ejemplares similares